<div id="readability-page-1"><div><p>Viatris (VTRS) has been back on investors’ radar after UBS shifted to a more positive stance on the stock. This move coincides with management changes and ongoing global expansion efforts.</p> <p>See our latest analysis for Viatris.</p> <p>The UBS upgrade and management reshuffle come on top of a sharp rebound in sentiment, with Viatris’ 90-day share price return of 47.85% and 1-year total shareholder return of 59.90% pointing to momentum that has recently picked up.</p> <p>If this renewed interest in healthcare names has you looking wider, it could be a good moment to scan our 25 healthcare AI stocks as potential next ideas to research.</p> <p>With the share price rallying, UBS lifting its target to US$18, and an intrinsic value estimate implying a large discount, the key question now is whether Viatris still trades below its fundamentals or if the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 27.3% Overvalued</h2> <p>Compared with the most followed narrative fair value of about $12.67, Viatris at $16.13 is framed as fully valued and then some, setting up a valuation built on improving margins and future profitability.</p> <blockquote> <p><em>Progress in developing and launching higher-margin complex generics, biosimilars, and innovative branded products (e.g., fast-acting meloxicam, ophthalmology assets) will improve gross margins and stabilize earnings by reducing exposure to price-sensitive, low-margin basic generics.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Curious what kind of revenue profile, margin lift, and earnings path are needed to support this richer valuation? The narrative leans on ambitious profit recovery, a step change in profitability, and a premium future earnings multiple more often associated with faster growing sectors. The real question is how those moving parts fit together over the next few years.</p> <p><strong>Result: Fair Value of $12.67 (OVERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, you still need to weigh the risk that ongoing price pressure on mature generics or integration setbacks at key facilities could limit the profit recovery story.</p> <p>Find out about the key risks to this Viatris narrative.</p> <h2>Another Lens: Multiples Point to Deep Discount</h2> <p>While the popular narrative flags Viatris at about 27.3% overvalued versus a US$12.67 fair value, the current P/S of 1.3x looks far lower than peers at 3.9x and the industry at 4.3x, and below a fair ratio of 3.6x. Is sentiment out of sync with the numbers?</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7dfe8d9-e220-4110-a371-abaae9d1b082/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7dfe8d9-e220-4110-a371-abaae9d1b082/chart/ps-multiple-vs-industry"/><figcaption>NasdaqGS:VTRS P/S Ratio as at Feb 2026</figcaption></figure><h2> Build Your Own Viatris Narrative</h2> <p>If you are not fully on board with this view or prefer to test your own assumptions against the numbers, you can build a tailored thesis in just a few minutes. To get started, use Do it your way.</p> <p>A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>If Viatris has sharpened your focus, do not stop here, use the screener to line up your next set of quality ideas before others move first.</p> <ul> <li>Target value opportunities by reviewing 51 high quality undervalued stocks that pair solid financial profiles with prices that may not fully reflect their fundamentals yet.</li> <li>Prioritise resilience with 85 resilient stocks with low risk scores, highlighting companies that score well on stability so you are not relying on luck when conditions get tougher.</li> <li>Get an early look at potential future leaders via our screener containing 24 high quality undiscovered gems, focusing on lesser known names with fundamentals you can actually scrutinise.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

ARKG

VTRS

IBBQ

<p>Viatris (VTRS) has gained investor attention following a UBS upgrade and management changes, with a 90-day share price return of 47.85%. UBS raised its price target to $18, while the stock is considered overvalued at $16.13 compared to a fair value of $12.67. The company aims to improve margins through higher-margin products, but risks remain from price pressures on generics. Despite being flagged as overvalued, Viatris' P/S ratio of 1.3x is lower than industry peers, suggesting potential misalignment between sentiment and fundamentals.</p>

A Look At Viatris (VTRS) Valuation After UBS Upgrade And Raised Price Target